Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study
Miao Wang,1,* Jin Shi,2,* Kepei Zhang,1,* Jie Hong,2,* Xinwei Peng,2 Yu Tian,1 Wei Lu,3 Ke Li,2 Zengliang Wang,4 Feng Li,1 Zhijie Zhang,2 Guojiang Mei1 1Department of Internal Medicine of Traditional Chinese Medicine, Longhua Hospital, Shanghai University of Tradition...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-03-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-and-safety-of-longyizhengqi-granule-in-treatment-of-mild-covi-peer-reviewed-fulltext-article-IDR |
| _version_ | 1797866267061780480 |
|---|---|
| author | Wang M Shi J Zhang K Hong J Peng X Tian Y Lu W Li K Wang Z Li F Zhang Z Mei G |
| author_facet | Wang M Shi J Zhang K Hong J Peng X Tian Y Lu W Li K Wang Z Li F Zhang Z Mei G |
| author_sort | Wang M |
| collection | DOAJ |
| description | Miao Wang,1,* Jin Shi,2,* Kepei Zhang,1,* Jie Hong,2,* Xinwei Peng,2 Yu Tian,1 Wei Lu,3 Ke Li,2 Zengliang Wang,4 Feng Li,1 Zhijie Zhang,2 Guojiang Mei1 1Department of Internal Medicine of Traditional Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of Epidemiology and Health Statistics, Fudan University, Shanghai, People’s Republic of China; 3Department of Nursing, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 4Department of Epidemiology, School of Public Health, Shandong University, Jinan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhijie Zhang, Department of Epidemiology and Health Statistics, School of Public Health, Fudan University, Xuhui District, School of Medicine Road, 130, Shanghai, People’s Republic of China, Tel +86-21-54237410, Email epistat@gmail.com; Guojiang Mei, Department of Internal Medicine of Traditional Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai, 200032, People’s Republic of China, Tel + 86-21-64385700, Email mgj_761014@sina.comPurpose: This study aimed to evaluate the clinical efficacy of Longyizhengqi granule, a traditional Chinese medicine, in patients with mild COVID-19.Patients and Methods: We conducted a prospective study including mild COVID-19 participants conducted at Mobile Cabin Hospital in Shanghai, China. Participants were assigned to receive Longyizhengqi granule or conventional treatment. The primary outcome was the time for nucleic acid to turn negative and the secondary outcomes are hospital stay and changes in cycle threshold (Ct) values for N gene and Orf gene. Multilevel random-intercept model was performed to analyze the effects of treatment.Results: A total of 3243 patients were included in this study (Longyizhengqi granule 667 patients; conventional treatment 2576 patients). Age (43.5 vs 42.1, p< 0.01) and vaccination doses (not vaccinated: 15.8% vs 21.7%, 1 dose: 3.5% vs 2.9%, 2 doses: 27.9% vs 25.6%, 3 doses: 52.8% vs 49.8%. p< 0.01) show statistical difference between Conventional treatment group and LYZQ granules group. The use of Longyizhengqi granule could significantly reduce the time for nucleic acid to turn negative (14.2 days vs 10.7 days, p< 0.01), shorten hospital stay (12.5 days vs 9.9 days, p< 0.01), and increase the changes in Ct value for N gene (8.44 vs 10.33, p< 0.01) and Orf gene (7.31 vs 8.44, p< 0.01) to approximately 1.5. Moreover, the difference in the changes of Ct values on the 4th, 6th, 8th, and 10th days seem to increase between two groups. No serious adverse events were reported.Conclusion: Longyizhengqi granule might be a promising drug for the treatment of mild COVID-19, and it might be beneficial to effectively shorten the negative transition time of nucleic acid, the total days of hospitalization, and increase the changes of Ct values. Long-term randomized controlled trials with follow-up evaluations are required to confirm its long-term efficacy.Keywords: COVID-19, Omicron variant, traditional Chinese medicine, prospective study |
| first_indexed | 2024-04-09T23:21:17Z |
| format | Article |
| id | doaj.art-ebf380f08b664921a8b0b4f32bec52d9 |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-04-09T23:21:17Z |
| publishDate | 2023-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-ebf380f08b664921a8b0b4f32bec52d92023-03-21T18:11:20ZengDove Medical PressInfection and Drug Resistance1178-69732023-03-01Volume 161611161882401Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective StudyWang MShi JZhang KHong JPeng XTian YLu WLi KWang ZLi FZhang ZMei GMiao Wang,1,* Jin Shi,2,* Kepei Zhang,1,* Jie Hong,2,* Xinwei Peng,2 Yu Tian,1 Wei Lu,3 Ke Li,2 Zengliang Wang,4 Feng Li,1 Zhijie Zhang,2 Guojiang Mei1 1Department of Internal Medicine of Traditional Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of Epidemiology and Health Statistics, Fudan University, Shanghai, People’s Republic of China; 3Department of Nursing, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 4Department of Epidemiology, School of Public Health, Shandong University, Jinan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhijie Zhang, Department of Epidemiology and Health Statistics, School of Public Health, Fudan University, Xuhui District, School of Medicine Road, 130, Shanghai, People’s Republic of China, Tel +86-21-54237410, Email epistat@gmail.com; Guojiang Mei, Department of Internal Medicine of Traditional Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai, 200032, People’s Republic of China, Tel + 86-21-64385700, Email mgj_761014@sina.comPurpose: This study aimed to evaluate the clinical efficacy of Longyizhengqi granule, a traditional Chinese medicine, in patients with mild COVID-19.Patients and Methods: We conducted a prospective study including mild COVID-19 participants conducted at Mobile Cabin Hospital in Shanghai, China. Participants were assigned to receive Longyizhengqi granule or conventional treatment. The primary outcome was the time for nucleic acid to turn negative and the secondary outcomes are hospital stay and changes in cycle threshold (Ct) values for N gene and Orf gene. Multilevel random-intercept model was performed to analyze the effects of treatment.Results: A total of 3243 patients were included in this study (Longyizhengqi granule 667 patients; conventional treatment 2576 patients). Age (43.5 vs 42.1, p< 0.01) and vaccination doses (not vaccinated: 15.8% vs 21.7%, 1 dose: 3.5% vs 2.9%, 2 doses: 27.9% vs 25.6%, 3 doses: 52.8% vs 49.8%. p< 0.01) show statistical difference between Conventional treatment group and LYZQ granules group. The use of Longyizhengqi granule could significantly reduce the time for nucleic acid to turn negative (14.2 days vs 10.7 days, p< 0.01), shorten hospital stay (12.5 days vs 9.9 days, p< 0.01), and increase the changes in Ct value for N gene (8.44 vs 10.33, p< 0.01) and Orf gene (7.31 vs 8.44, p< 0.01) to approximately 1.5. Moreover, the difference in the changes of Ct values on the 4th, 6th, 8th, and 10th days seem to increase between two groups. No serious adverse events were reported.Conclusion: Longyizhengqi granule might be a promising drug for the treatment of mild COVID-19, and it might be beneficial to effectively shorten the negative transition time of nucleic acid, the total days of hospitalization, and increase the changes of Ct values. Long-term randomized controlled trials with follow-up evaluations are required to confirm its long-term efficacy.Keywords: COVID-19, Omicron variant, traditional Chinese medicine, prospective studyhttps://www.dovepress.com/efficacy-and-safety-of-longyizhengqi-granule-in-treatment-of-mild-covi-peer-reviewed-fulltext-article-IDRcovid-19omicron varianttraditional chinese medicineprospective study |
| spellingShingle | Wang M Shi J Zhang K Hong J Peng X Tian Y Lu W Li K Wang Z Li F Zhang Z Mei G Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study Infection and Drug Resistance covid-19 omicron variant traditional chinese medicine prospective study |
| title | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study |
| title_full | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study |
| title_fullStr | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study |
| title_full_unstemmed | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study |
| title_short | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study |
| title_sort | efficacy and safety of longyizhengqi granule in treatment of mild covid 19 patients caused by sars cov 2 omicron variant a prospective study |
| topic | covid-19 omicron variant traditional chinese medicine prospective study |
| url | https://www.dovepress.com/efficacy-and-safety-of-longyizhengqi-granule-in-treatment-of-mild-covi-peer-reviewed-fulltext-article-IDR |
| work_keys_str_mv | AT wangm efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT shij efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT zhangk efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT hongj efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT pengx efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT tiany efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT luw efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT lik efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT wangz efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT lif efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT zhangz efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy AT meig efficacyandsafetyoflongyizhengqigranuleintreatmentofmildcovid19patientscausedbysarscov2omicronvariantaprospectivestudy |